MOTS-c + BPC-157 is a two-peptide research blend that pairs a mitochondrial-genome-encoded metabolic-regulator peptide with a synthetic gastric pentadecapeptide studied preclinically for cytoprotection and tissue repair. Of the blends in this library it is one of the least mechanistically intuitive: the two components come from largely separate literatures — metabolism and exercise biology on one side, injury repair on the other. The combination itself has never been studied.
Composition
The blend contains two distinct peptides. MOTS-c ("mitochondrial open reading frame of the twelve-S rRNA type-c") is a 16-amino-acid peptide encoded within the mitochondrial genome, in a short open reading frame inside the 12S rRNA region [1]. BPC-157 is a synthetic 15-amino-acid peptide corresponding to a fragment of a protein identified in human gastric juice [2]. There is no single molecular formula for the blend; each component retains its own identity and the proportion of each is set by the vendor. VialTalk does not currently track a catalog listing for this blend, so no catalog vial label is given here.
What each component contributes
MOTS-c — metabolic signalling. MOTS-c is described as a metabolic regulator whose most-reported mechanism is activation of AMPK, with downstream effects on glucose handling and insulin sensitivity; it has also been reported to translocate to the nucleus under metabolic stress [1]. In cultured cells, MOTS-c raised markers of mitochondrial biogenesis and the mitochondrial fusion proteins OPA1 and MFN2, and fusion was required for MOTS-c-induced GLUT4 translocation [3]. A study combining human participants and laboratory models reported that MOTS-c facilitated trafficking of the membrane-repair protein TRIM72 to the muscle cell membrane and attenuated membrane damage in vitro [4]. Not all findings point one way: in adipose-derived mesenchymal stromal cells from donors with obesity, exogenous MOTS-c activated AMPK signalling but blunted the cells' reparative function [5].
BPC-157 — repair signalling. Reported mechanisms, which remain hypothesised, include VEGFR2-linked angiogenesis and modulation of the nitric oxide system [2]. A 2025 review describes Akt-eNOS and ERK1/2 involvement and fibroblast activation, particularly in poorly vascularised tissue such as tendon [8]. In rat tendon fibroblasts, BPC-157 increased cell survival under oxidative stress and cell migration, with FAK and paxillin activation [9].
The rationale for pairing them. The pairing is usually framed as metabolic and mitochondrial support (MOTS-c) alongside local tissue-repair signalling (BPC-157), most often in recovery and athletic-performance discussions. Both appear together in a 2026 sports-medicine review of unapproved peptides, which notes favourable animal findings for many such peptides but scarce rigorous human safety data [12]. The rationale is a hypothesis; the mesenchymal stromal cell finding [5] is a reminder that a metabolic activator is not automatically pro-repair.
Combination evidence — the honest boundary
No study of MOTS-c and BPC-157 given together was found. A PubMed search combining the two names returned two records, both reviews that discuss each peptide separately among many others: a 2026 narrative review of approved and unapproved peptides in sports medicine [12] and a 2026 review of FDA compounding-committee evaluations of synthetic peptides [13]. Neither reports an experiment testing the two together.
Evidence tiers by component:
- MOTS-c in humans. Human data are largely observational, associating circulating MOTS-c with metabolic or fitness measures [1]. In a randomised study of 30 participants, plasma MOTS-c and humanin responses to acute endurance and resistance exercise were measured [6] — this concerns the body's own MOTS-c, not supplied peptide. A randomised, placebo-controlled Phase 2a trial of MOTS-c on insulin sensitivity in adults with prediabetes is registered and recruiting, with no results posted [7]. Well-powered completed interventional trials are essentially absent [1].
- MOTS-c in animals and cells. The work is predominantly rodent and cell work on insulin sensitivity and metabolic decline [1], plus mechanistic cell studies [3][5].
- BPC-157 in humans. There are no completed, published controlled trials [2]; a 2025 review counted three small pilot studies [8]; a systematic review found 35 of 36 included studies preclinical [10]; a Phase 2 hamstring-strain trial is recruiting [11].
- BPC-157 in animals and cells. The work consists predominantly of rodent studies from a small number of research groups [2].
The published work covers each peptide only on its own [1][2][12]. Nothing is known about interaction between the two, co-formulation stability, or whether MOTS-c's metabolic effects alter BPC-157's reported activity or vice versa.
Research context
The "exercise-mimetic" description sometimes attached to MOTS-c is more marketing than established science [1], and the breadth of effects reported for BPC-157 in animal models warrants a sceptical read until human data exist [2]. Blending the two adds to that uncertainty rather than resolving it. Treat it as two separately characterised, largely preclinical compounds, not a validated formulation.
Storage and handling
Store the sealed lyophilized product frozen or refrigerated, dry and protected from light, and avoid repeated freeze–thaw. Default to the more conservative storage window of the two components.
Quality and COA considerations
A meaningful COA must confirm identity of both peptides by mass spectrometry and report HPLC purity for each, with a per-component content breakdown rather than a single total. MOTS-c is a defined 16-mer and BPC-157 a defined 15-mer, so mass confirmation should match each expected molecular weight [1][2]. BPC-157 sequence-incorrect and under-filled product is a known market problem [2], and MOTS-c's popularity relative to its thin evidence base warrants sourcing scepticism [1].
Key references
[1] VialTalk monograph — MOTS-c — https://vialtalk.com/forum/peptide-research-library/mots-c-research-monograph-mitochondrial-peptide-metabolic
[2] VialTalk monograph — BPC-157 — https://vialtalk.com/forum/peptide-research-library/bpc-157-research-monograph-structure-mechanism-evidence
[3] Mitofusion is required for MOTS-c induced GLUT4 translocation — https://pubmed.ncbi.nlm.nih.gov/34253808/
[4] MOTS-c participates in plasma membrane repair via TRIM72 translocation — https://pubmed.ncbi.nlm.nih.gov/39267782/
[5] MOTS-c blunts reparative function in human mesenchymal stromal cells (2026) — https://pubmed.ncbi.nlm.nih.gov/42324588/
[6] Acute exercise and circulating mitochondrial-derived peptides in humans — https://pubmed.ncbi.nlm.nih.gov/34351816/
[7] NCT07505745 — MOTS-c for insulin sensitivity in prediabetes (Phase 2a, recruiting) — https://clinicaltrials.gov/study/NCT07505745
[8] Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (2025) — https://pubmed.ncbi.nlm.nih.gov/40789979/
[9] BPC 157 tendon healing: outgrowth, cell survival and migration (rat tendon fibroblasts) — https://pubmed.ncbi.nlm.nih.gov/21030672/
[10] Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review — https://pubmed.ncbi.nlm.nih.gov/40756949/
[11] NCT07437547 — BPC 157 for hamstring strain (Phase 2, recruiting) — https://clinicaltrials.gov/study/NCT07437547
[12] Mendias & Awan, Sports Med 2026 — Approved and Unapproved Peptide Therapies — https://pubmed.ncbi.nlm.nih.gov/41966639/
[13] Willis & Vu, Int J Pharm Compd 2026 — Synthetic Peptides in Pharmacy Compounding — https://pubmed.ncbi.nlm.nih.gov/42752426/
Research-use note: This monograph is an educational summary of the published literature on MOTS-c and BPC-157. The MOTS-c + BPC-157 combination has not been studied in any published human or animal experiment known to VialTalk, and neither peptide is an approved drug. Nothing here is medical advice or a usage recommendation.